NeuroOne Partners with University of Minnesota to Advance Targeted Epilepsy Treatment Platform

NeuroOne Medical Technologies Corporation has announced a collaboration with the University of Minnesota Medical School's Department of Neurology to advance research on targeted epilepsy therapies using the company's stereoelectroencephalography-based platform. The partnership focuses on developing localized drug delivery systems that could transform treatment for neurological disorders by minimizing systemic side effects while improving clinical outcomes.

The study, led by Professor Sandipan Pati, Director of the Epilepsy Division at the University of Minnesota, will evaluate novel therapeutics delivered directly into specific brain regions involved in sustaining seizures. According to Dr. Pati, localized intracerebral delivery represents an important emerging direction for improving precision in epilepsy treatment while minimizing systemic side effects. The research builds on existing clinical practices that use FDA-cleared intracranial electrodes for recording brain activity and performing therapeutic interventions.

NeuroOne's President and CEO Dave Rosa emphasized the significance of the collaboration, stating that the University of Minnesota is at the forefront of next-generation epilepsy research. The company believes this partnership will support development of a first-in-human study utilizing their technology for intracerebral treatment of epileptic seizures. If successful, this approach could redefine seizure care and establish a new era of precision brain-directed therapy.

The research program will begin with large animal models and, if primary objectives are met, progress to human studies. Current preclinical studies are focused on evaluating the feasibility, safety, and physiological effects of intracerebral drug infusion using minimally invasive intracranial platforms, including ultra-thin electrode-based systems designed to reduce tissue disruption. These studies aim to better understand how targeted delivery influences seizure networks and brain-body interactions.

NeuroOne's technology platform includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain, and OneRF Trigeminal Nerve Ablation System. These solutions offer the potential to reduce hospitalizations and surgical procedures while lowering costs and improving patient outcomes through combination diagnostic and therapeutic functions. For more information about the company's technology and research initiatives, visit nmtc1.com.

The collaboration represents a significant step toward developing more precise and individualized therapies for epilepsy patients. By combining academic research expertise with commercial medical technology development, the partnership aims to address longstanding challenges in neurological treatment, particularly the balance between therapeutic efficacy and systemic toxicity. The research findings could have broader implications for treating other neurological disorders beyond epilepsy, potentially establishing new paradigms for brain-targeted therapies.